Advances in drug therapy for advanced medullary thyroid carcinoma
Medullary thyroid cancer has a low incidence but high malignancy,a tendency to early lymph node and distant metastasis,and a poor prognosis.At present,surgery is still the effective treatment for medullary thyroid cancer,but for patients with advanced medullary thyroid cancer that cannot be cured by surgery,participating in drug clinical trials is an effective treatment.The main cause of medullary thyroid cancer is RET proto-oncogene mutation,which is mainly divided into two categories:sporadic and hereditary medullary thyroid cancer.Among them,sporadic medullary thyroid carcinoma is the most common in clinical practice,while hereditary medullary thyroid carcinoma is less common in clinical practice,but has the characteristics of lower age of onset and higher degree of malignancy.Compared with other tumor types,there is still a lack of effective treatment for patients with advanced medullary thyroid cancer,and there is still an urgent need to develop effective therapeutic drugs.This article introduces the clinical research on advanced medullary thyroid cancer according to the targets and signaling pathways related to the pathogenesis of medullary thyroid cancer,and briefly introduces the main results of the study and the corresponding drug-related adverse events.
万方数据
维普
